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Abstract
Cancer cells typically experience higher oxidative stress than normal cells, such that elevating pro-
oxidant levels can trigger cancer cell death. Although pre-exposure to mild oxidative agents will 
sensitize cancer cells to radiation, this pre-exposure may also activate the adaptive stress defense 
system in normal cells. Ascorbic acid (AA) is a prototype redox modulator that when infused 
intravenously appears to kill cancers without injury to normal tissues; however, the mechanisms 
involved remain elusive. In this study, we show how AA kills cancer cells and sensitizes prostate 
cancer to radiation therapy, while also conferring protection upon normal prostate epithelial cells 
against radiation-induced injury. We found that the NF-κB transcription factor RelB is a pivotal 
determinant in the differential radiosensitization effects of AA in prostate cancer cells and normal 
prostate epithelial cells. Mechanistically, high ROS concentrations suppress RelB in cancer cells. 
RelB suppression decreases expression of the sirtuin SIRT3 and the powerful antioxidant MnSOD, 
which in turn increases oxidative and metabolic stresses in prostate cancer cells. In contrast, AA 
enhances RelB expression in normal cells, improving antioxidant and metabolic defenses against 
radiation injury. In addition to showing how RelB mediates the differential effects of AA on 
cancer and normal tissue radiosensitivities, our work also provides a proof of concept for the 
existence of redox modulators that can improve the efficacy of radiotherapy while protecting 
against normal tissue injury in cancer settings.
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Introduction
Prostate cancer is the most prevalent cancer in the United States and is the second leading 
cause of cancer deaths in men (1). The predominant prostate cancer therapy, ionizing 
radiation (IR), is used to treat more than 750,000 patients per year (2). Unfortunately, the 
therapeutic efficacy of IR tends to decrease when cancer cells develop adaptive responses to 
resist it. Even with modern conformal radiation therapy, biochemical failure occurs in 
approximately 45% of patients with a locally confined disease (3). Additionally, 
corresponding with the widespread use of high-dose IR to treat prostate cancer, the 
incidence of radiation-related genitourinary toxicity has increased (4). Therefore, novel 
therapeutic strategies to enhance both radiosensitization in cancer cells and radioprotection 
in normal tissues are urgently needed.
Cancer cells are usually under higher oxidative stress than normal cells, and cellular redox 
state is thought to be important to cell fate. The level of oxidative stress is also critical to 
radiation response (5, 6). In addition to directly damaging DNA, IR can produce a large 
amount of free radicals that cause cell death (5). Due to water radiolysis, IR causes excess 
superoxide generation and allows leakage of electrons from the electron transport chain 
(ETC), resulting in mitochondrial dysfunction (7). However, IR also tends to induce adaptive 
reactive oxygen species (ROS) defense systems in cancers, which may lead to 
radioresistance (8). While increasing radiation intensity can improve the ability to control 
cancer growth, it presents the significant risks of increasing unwanted side effects, including 
injury to normal tissues and reduced quality of life for cancer survivors. Thus, an attractive 
radiation therapy would be one that exploits the intrinsic differences in the cellular redox 
statuses of normal cells and cancer cells by selectively boosting ROS generation in cancer 
cells to push them into oxidative stress overload while stimulating adaptive responses in 
normal cells.
Ascorbic acid (AA), better known as vitamin C, has a somewhat controversial history as a 
therapeutic drug for cancer treatment (9, 10). Emerging studies suggest that only 
intraperitoneal or intravenous AA, and not orally administered AA, can reach 
pharmacological concentrations that kill cancer (10, 11). However, although clinical trials of 
AA have demonstrated the differences between administration routes and the safety of 
intravenous AA (12, 13), there is still a lack in understanding the mechanisms by which AA 
kills cancer cells. In general, the cytotoxicity induced by AA seems to be primarily mediated 
by hydrogen peroxide (H2O2) generated in extracellular fluids (14). A recent elegant study 
demonstrated that pharmacologic ascorbate enhances the cytotoxic effects of ionizing 
radiation in pancreatic cancer cell lines, but not in nontumorigenic pancreatic ductal 
epithelial cells because pancreatic cancer is sensitive to H2O2 (15). Thus, the cytotoxic effect 
of AA may well be dependent on the local redox environment of the cancer cells.
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Mounting evidence suggests that ROS-mediated NF-κB activation is involved in the 
radiation resistance of cancers (16). The NF-κB family includes NF-κB1 (p50/p105), NF-
κB2 (p52/p100), c-Rel, RelA (p65), and RelB. Recent studies have demonstrated that RelB 
is uniquely expressed at a high level in prostate cancer with high Gleason scores, suggesting 
that RelB plays an important role in the radioresistance of prostate cancer (17, 18). The 
present study examined the effects of AA on cell survival and on the responses to radiation 
of prostate cancer cells and normal prostate epithelial cells in vitro and in vivo. We found 
that the intrinsic differences in the cellular redox state of normal and cancer cells account, in 
part, for the differential effects of AA on the modulation of cellular redox status. The 
expression of RelB in normal and cancer cells serves as a central regulator for their opposing 
responses to radiotherapy.
Materials and Methods
Cell culture, cell transfection, and reagents
Human prostate cancer cell lines LNCaP and PC3, as well as normal human prostate 
epithelial viral transformed PZ-HPV-7 (PZ) cells, were obtained from American Type 
Culture Collection. These cell lines are routinely checked for morphological and growth 
changes to probe for cross-contaminated or genetically drifted cells. All cell lines used have 
been reauthenticated using the Short Tandem Repeat (STR) profiling service by ATCC. 
Normal human epithelial cells (PrEC) were purchased from Lonza. The cells were cultured 
and maintained in the manufacturer’s suggested media. Plasmid-cloned RelB cDNA and 
siRNA for knocking down RelB were transfected into LNCaP and PC3 cells using a 
Lipofectamine 2000 kit (Life Technologies) according to the manufacturer’s instructions. 
AA (powder, USP/FCC grade, Fisher Chemical) was prepared as a 1 M stock solution in 
sterile water, with sodium hydroxide added dropwise to adjust the pH to 7.0, as previously 
described. H2O2 (Sigma) solutions were prepared freshly prior to application to the cells.
Treatment and cell survival analysis
Cell survival rates were quantified by colony survival and MTT assays. For colony survival 
analyses, the cells were plated in 6-well plates at low densities and then treated with 0 to 1.0 
mM AA for 2 h, which corresponds to the clinical time course of intravenous AA 
administration (19). The formed colonies were washed with 1×PBS and stained with a 
crystal violet dye for clonogenic assay. The surviving fraction was calculated as the ratio of 
the number of colonies formed to the number of cells effectively plated.
For the MTT assay, cells were seeded in flat-bottomed 96-well plates, treated with 0 to 64 
mM AA for 2 h, washed with fresh media, and incubated for 2 doubling times in the absence 
of AA. Cell viability was detected by an MTT assay kit (Trevigen) following the standard 
protocol. The IC50 for each cell line was calculated from a dose-response curve using 
GraphPad Prism 6.0 software (GraphPad software). For evaluations of combination therapy, 
PC3 and PZ cells were treated with AA, IR or a combination of the two. IR was performed 
at 1 h after AA treatment by a 250 kV X-ray machine (Faxitron X-ray Corp.) with peak 
energy of 120 kV, 0.05 mm Al filter, at a dose of 0 to 6 Gy. After total 2 h exposure to AA, 
cells were incubated for 2 doubling times in the absence of AA and assessed by MTT assay. 
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Combination Index (CI) values were calculated by CompuSyn 1.0 (CompuSyn) and the 
effects of combined IR and AA treatment were evaluated according to the acknowledged 
range of CI as published (20).
Animals
Four- to five-week-old male NCRNU (nu/nu athymic nude) mice were obtained from 
Taconic (Hudson). For formation of xenograft tumors, 1.8×106 cells mixed in Matrigel (BD 
Biosciences) were subcutaneously injected into the right flanks of the mice. Tumor volumes 
were routinely measured and their sizes calculated on the basis of a protocol described 
elsewhere (21). Animals with an average tumor size of 350 mm3 were randomized into 4 
groups (n=10) and treatment commenced with intraperitoneal injection as follows: (i) 
control, saline once daily; (ii) AA, 4.5 g/kg once daily; (iii) IR, 2 Gy once every other day; 
(iv) IR+AA. The dosage of AA was determined by conversion of clinical trial data and with 
reference to recent studies (22). For combination treatments, IR was performed at 1 h after 
AA injection. After treatment, the mice were observed daily and humanely killed when the 
tumor reached the maximum size of 1500 mm3. The tumor, prostate, and bladder tissues 
were collected for protein and RNA analysis. All animal experimental procedures were 
approved by the Institutional Animal Care and Use Committee of the University of 
Kentucky (Lexington, KY), Approval Protocol No. 01077M2006.
Quantification of ROS level
An Amplex Red assay was used to quantify the levels of extracellular H2O2 after AA and IR 
treatments. Briefly, cells were incubated with 50 μM Amplex Red reagent (ThermoFisher) at 
37°C for 10 min. Fluorescence was detected at ex/em 550/590 nm using a Gemini XPS 
Microplate Reader (Molecular Devices). The extracellular H2O2 level was calculated by a 
standard curve and normalized to the cell number. MitoSox Red (ThermoFisher), a highly 
selective mitochondrial superoxide indicator for live cells, was used to estimate the levels of 
superoxide, and Mitotracker green FM (ThermoFisher) was used to locate mitochondria. 
Rotenone (200 nM, Sigma), known to be a mitochondrial superoxide inducer, was used as a 
positive control. To account for superoxide-specific fluorescence, the cells were pretreated 
with 100 units/mL PEG-SOD (Sigma) for 24 h followed by the treatment. In brief, cells 
were loaded with Mitotracker Green at 100 nM for 15 min followed by 5 μM MitoSox Red 
for 10 min at 37°C and rinsed 3 times with HBSS before measuring fluorescence. Cellular 
fluorescence intensity was detected using an Olympus IX71 fluorescence microscope and a 
Gemini XPS Microplate Reader at ex/em 510/580 nm.
Catalase and MnSOD treatments
To further determine the specific high ROS level induced by AA and radiation, PC3 cells 
were treated with various forms of catalase or MnSOD, including catalase (100u/mL), PEG-
CAT (200 U/mL), PEG-MnSOD (100 U/mL) or adenovirus MnSOD. Catalase, PEG-
catalase and PEG-MnSOD were purchased from Sigma-Aldrich. For the adenovirus 
experiments, viral vectors utilized included AdCMVEmpty (AdEmpty) and 
AdCMVMnSOD (AdMnSOD), manufactured by Viraquest, Inc. (North Liberty, IA) as 
previously described (23, 24). Approximately 106 PC3 cells were plated in a 100 mm2 tissue 
culture dish and incubated with the adenovirus constructs for 24 h. Media were replaced 
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with 5 mL of complete media for an additional 24 h before cells were harvested for MTT 
assay or treated for ROS measurements.
Measurement of oxygen consumption rates, ATP, and lactate production
To determine whether AA changes mitochondrial function in cancer and normal cells, a 
Seahorse Bioscience XF96 Extracellular Flux Analyzer was used to measure oxygen 
consumption rates (OCR) after 2 h of treatment with 4 mM AA. The data were normalized 
with protein levels and expressed as the OCR in pmol/min/μg protein. Cellular ATP 
concentrations were measured using an ATP Assay kit (Biomedical Research Service 
Center). Extracellular and intracellular lactate levels were measured by a Lactate Assay kit 
(Biomedical Research Service Center). Data were normalized to the cell number, as 
indicated in each figure.
Western blots
Lysates from homogenized cells and tumor tissues were electrophoresed on a 10–12% (w/v) 
SDS-PAGE gel, transferred onto a nitrocellulose membrane, and subsequently incubated 
with primary antibodies against RelA, RelB, Bcl-xl, Bax, or GAPDH from Santa Cruz 
Biotech, or SIRT1 (Upstate Biotech), MnSOD (Upstate Biotech), SIRT3 (Cell Signaling), or 
β-actin (Sigma). All secondary antibodies were obtained from Santa Cruz Biotech. The blots 
were visualized using an enhanced chemiluminescence detection system (Amersham 
Pharmacia Biotech).
Real-time PCR
mRNA was isolated from cells and tissues using a MagNA Pure Compact RNA Isolation Kit 
(Roche) and reverse-transcribed using a Taqman reverse transcription kit (ThermoFisher) 
according to the manufacturer’s instructions, and then analyzed using a LightCycler® 480 
Real-Time PCR System (RT-PCR, Roche) with gene-specific primers. All primers were 
purchased from Invitrogen. Primer sequences for human genes were as follows:
RELB 5′-cacttcctgcccaaccac-3′ (forward) and 5′-gacacggtgccagagaaga-3′ 
(reverse); Bcl-xl 5′-agccttggatccaggagaa-3′ (forward) and 5′-
gctgcattgttcccatagagt-3′ (reverse); SIRT3 5′-cttgctgcatgtggttgatt-3′ (forward) and 
5′-cggtcaagctggcaaaag-3′ (reverse); β-actin 5′-ccaaccgcgagaagatga-3′ (forward) 
and 5′-ccagaggcgtacagggatag-3′ (reverse).
Primer sequences for mouse genes were as follows:
RelB 5′-gtgacctctcttccctgtcact-3′ (forward) and 5′-tgtattcgtcgatgatttccaa-3′ 
(reverse); Sirt3 5′-tcctctgaaaccggatgg-3′ (forward) and 5′-
tcccacacagagggatatgg-3′ (reverse); β-actin 5′-ctggctcctagcaccatga-3′ (forward) 
and 5′-acagtgaggccaagatggag-3′ (reverse).
NF-κB binding assay
Nuclear extracts from the treated and untreated PC3 and PZ cells were prepared by a nuclear 
extract kit (Active Motif). Binding activities of RelA and RelB were measured using an 
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ELISA-based TransAM NF-κB Family kit (Active Motif) according to the manufacturer’s 
protocol.
Chromatin immunoprecipitation
A Pierce™ Agarose ChIP Kit (ThermoFisher) was used to study RelB-mediated 
transcriptional regulation according to the manufacturer’s protocol. A potential RelB 
binding site was predicted in the promoter region of the human SIRT3 gene based on a 
search of the Ensembl genome database and a recent study (25). Briefly, chromatin was 
pulled down using a RelB antibody (Santa Cruz Biotech), and a DNA fragment containing 
an NF-κB element located in the SIRT3 promoter region was analyzed by quantitative PCR 
(qPCR) with LightCycler® 480 SYBR Green I Master kit (Roche). PCR primer sequences 
for SIRT3 were 5′-gaattatgaaatgagcacag-3′ (forward) and 5′-caggatagcaagaacgagca-3′ 
(reverse). Rabbit IgG antibody was used as a negative control. ChIP-qPCR data were 
normalized by input preparation.
Intracellular Catalase, Gpx and MnSOD enzymatic assay
The activities of catalase and Gpx were measured by a Catalase- specific activity assay kit 
(Abcam) and a Gpx Cellular activity assay Kit (Sigma) according to the manufacturers’ 
protocols, respectively. MnSOD activities were measured by the nitroblue tetrazolium-
bathocuproin sulfonate reduction inhibition method. Sodium cyanide (2 mM) was used to 
inhibit CuZnSOD activity as a previous study described (26).
Quantitative and statistical data analyses
Multiple independent experiments were conducted for each set of data presented. Image data 
were quantified using the quantitative imaging software Image-pro Plus 6.0 (Media 
Cybernetics). Toxicity comparisons of multiple groups were analyzed using ANOVA and a 
post-hoc test. Data represent the mean ± SEM. Kaplan-Meier survival curves and the log-
rank test were performed for comparison of the survival curves in animal experiments. 
Statistical significances of other experiments were analyzed using one-way ANOVA and 
Tukey’s multiple comparison tests. All analyses were performed with IBM SPSS 21.0 
software (Microsoft). Differences with an associated P <0.05 were considered to be 
significant.
Results
AA enhances radiosensitivity in prostate cancer cells but protects normal cells from 
radiotoxicity
To determine the cytotoxicity of AA in prostate cancer and normal cells, LNCaP, PC3, 
PrEC, and PZ cells were plated for colony survival assays and MTT assays. As shown in 
Fig. 1A and B, high doses of AA alone efficiently killed cancer cells but exerted no or 
minimal effect on normal cells. Interestingly, AA appears to be more efficient in killing 
aggressive prostate cancer PC3 cells than LNCaP cells. Based on a dose-effect curve, the 
IC50 values for PC3, LNCaP, PrEC, and PZ cell lines were quantified as 3.96 mM, 12.81 
mM, 36.56 mM, and 33.79 mM, respectively, indicating that AA has different cytotoxic 
effects on prostate cancer and normal cells.
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To determine the capacity of AA to sensitize prostate cancer cells to IR, we used the 
protocol for radiosensitization of PC3 cells described in our previous study (27), taking into 
consideration the relative AA IC50 value in clinical application (28). The total dose of AA 
was kept at 2 mM (for 1/2 IC50) or 4 mM (for the full IC50). Pretreatment with AA 
significantly increased the radiosensitivity of PC3 cells in a dose-dependent manner within 
an IR range of 0.5 to 6 Gy (Fig. 1C). Interestingly, pretreatment with AA resulted in the 
opposite effect in PZ cells, indicating that AA actually protects normal cells against the 
cytotoxicity induced by IR (Fig. 1C). To assess the combined effects of AA and IR, the CI 
value for each dose was calculated by CompuSyn software based on the Chou-Talalay 
method (20). A dose of 4 mM AA conformed to the Cl range description, in that it displayed 
a synergistic effect on IR from 1 to 6 Gy in PC3 cells (Table S1). On the contrary, both doses 
of AA in PZ cells displayed antagonistic effects on IR over a dose range of 0.5 to 6 Gy. 
These results suggest that equivalent pharmacological doses of AA can exert different 
radiosensitization effects in prostate cancer and normal cells.
AA differentially modulates cellular ROS levels in cancer and normal cells
To determine the effect of AA on redox homeostasis in cancer and normal cells, the levels of 
ROS and mitochondrial superoxide anion were measured with and without AA treatment. 
As shown in Fig. 2A, the basal level of extracellular H2O2 was slightly but significantly 
higher in prostate cancer cells than in normal cells. In comparison to the result in PZ cells, 
AA treatment induced a significant increase in ROS in prostate cancer cells, especially PC3 
cells (Fig 2A). Pretreatment with PEG-Catalase or catalase obviously inhibited such 
extracellular H2O2 increases and weakened toxicity of AA in PC3 cells (Fig. S1A and B). 
These results are consistent with previous reports that AA produces H2O2 by oxidative 
reaction with metal ions in extracellular fluid and exerts cytotoxic effects (14, 15).
To evaluate intracellular redox status, superoxide levels in mitochondria, the primary source 
of cellular ROS, were quantified in cancer and normal cells. Mitotracker green staining with 
negligible stimulated ROS was used to normalize MitoSox red to quantify mitochondrial 
superoxide anion induced by AA with rotenone as a positive control. AA induced 
superoxide generation in PC3 cells, but the effect was mitigated by adding PEG-SOD (Fig. 
S1C). Consistent with the results for cytotoxicity in Fig. 1, AA increased IR-induced 
superoxide generation in PC3 cells but decreased it in PZ cells (Fig. 2B). Increasing 
endogenous MnSOD expression in PC3 cells clearly decreased superoxide, especially IR-
induced superoxide generation after AA treatment (Fig S1D). These results suggest that AA 
amplifies IR-induced cellular ROS level in cancer cells. They also suggest that AA 
suppresses IR-induced ROS generation in normal cells.
AA differentially modulates mitochondrial function in cancer and normal cells
To test whether altering cellular redox status is associated with mitochondrial function, the 
oxygen consumption rate (OCR) in the AA-treated cells was measured using a Seahorse 
Bioscience XF96 OxygenFlux Analyzer. As shown in Fig. 3A, AA treatment decreased 
basal, ATP-linked, and maximal OCR but not reserve capacity in PC3 cells. In contrast, AA 
treatment increased the maximal OCR and reserve capacity of PZ cells. To test if such 
effects modulate the energy production of cells, the cellular ATP and lactate levels were 
Wei et al. Page 7
Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
determined with and without treatment. As expected, pretreatment with AA significantly 
diminished intracellular ATP when combined with IR, but increased both extracellular and 
intracellular lactate production in PC3 cells (Fig. 3B, C, D). In contrast, combined AA and 
IR treatment increased ATP production but decreased lactate concentrations in normal PZ 
cells (Fig. 3B, C, D). These results suggest that AA-mediated alterations in cellular 
oxidative and metabolic stresses play pivotal roles in the radiation response of both prostate 
cancer and normal cells. Importantly, AA exacerbates mitochondrial dysfunction in cancer 
cells, but alleviates radiation-induced mitochondrial dysfunction in normal cells.
AA inversely regulates RelB expression in cancer and normal cells
NF-κB signaling is involved in multiple biological processes responsive to ROS (29). The 
best known activator of NF-κB is RelA, which is associated with radioresistance in many 
types of cancer. Our previous findings demonstrate that RelB is also highly expressed in 
prostate cancer cells and is a major contributor to radioresistance (18, 30). To probe which 
member of the NF-κB family is affected by AA, we first determined whether AA regulates 
the expression of RelA and RelB in prostate cancer and normal cells at the mRNA and 
protein levels. While AA slightly increased RelA protein levels in both cancer and normal 
cells, AA strongly down-regulated RelB protein and mRNA in cancer cells and up-regulated 
RelB in normal cells (Fig. 4A). To further verify this finding, an NF-κB binding assay was 
performed to confirm AA activation or suppression of RelA and RelB. As shown in Fig. 4B, 
RelB binding activity was strongly suppressed in PC3 cells but apparently activated in PZ 
cells after AA treatment alone. Importantly, pretreatment with AA significantly diminished 
IR-induced RelB activation in PC3 cells. No significant effect of AA was observed on RelA 
binding activity, but a small but significant increase was observed with combination 
treatment in PZ cells.
To further confirm the transcription effect of RelB on its target genes, the NF-κB-regulated 
genes Bcl-xL and Bax were quantified to verify the regulation of the NF-κB pathway by AA 
in prostate cancer and normal cells. Consistently, AA down-regulated Bcl-xL but up-
regulated Bax in PC3 cells, while the reverse effect of AA was observed in PZ cells (Fig. 
S2A). Finally, to confirm the role of RelB in AA-induced cell killing of prostate cancer cells, 
the level of RelB was manipulated by either overexpression of RelB in LNCaP cells or 
knockdown of RelB in PC3 cells. AA-mediated cytotoxicity was increased in RelB-silenced 
PC3 cells but reduced in RelB-overexpressed LNCaP cells (Fig. 4C, Fig. S2A).
RelB acts as a central regulator in response to oxidative and metabolic stresses in cancer 
cells
Generally, the radiosensitization we find in cancer cells is due to the oxidative and metabolic 
stresses induced by AA. Since our data showed that RelB plays an important role in AA-
induced cell killing of prostate cancer cells, it was necessary to verify the functions of RelB 
in oxidative and metabolic stresses. As shown in Fig 5A, knockdown of RelB reduced basal 
ATP production and increased intracellular lactate level. When treated with AA, IR or 
combination treatment, RelB-silenced PC3 cells displayed more aggravated metabolic stress 
compared to the control group (Fig 5A). The OCR data further confirmed the effect of 
suppressing RelB on mitochondrial function in cancer cells, especially when treated with 
Wei et al. Page 8
Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
AA and IR (Fig 5B). To confirm the role of RelB in response to oxidative stress, the 
activities of ROS related enzymes were evaluated in RelB-silenced PC3 cells. As shown in 
Fig 5C, 5D knocking down RelB markedly weakened the ability of ROS elimination in 
cancer cells which was revealed by the reduction of catalase, GPX and MnSOD activities. 
These results confirm the role of RelB in oxidative and metabolic regulations. Furthermore, 
they confirm that RelB may be a central regulator that adjudicates the differential effects of 
AA in normal and cancer cells.
RelB transcriptionally regulates SIRT3 in response to AA treatment
SIRT3, a member of the sirtuin family of NAD+-dependent protein deacetylases, is known 
to play a critical role in maintaining mitochondrial function, ROS response, and cell 
proliferation, as well as in inducing radioresistance in cancers. Recently, a sequential action 
of SIRT1-RelB-SIRT3 has been reported in sepsis (31), but the related mechanisms remain 
to be fully elucidated. To probe the relationship of SIRT3 with RelB in AA-induced 
cytotoxicity in cancer cells and the protective effect in normal cells, the levels of SIRT1 and 
SIRT3 relative to RelB were quantified in PC3 and PZ cells. As shown in Fig. 6A, up-
regulation and down-regulation of SIRT3 correlated with RelB in the AA-treated cells, but 
no significant changes were observed in SIRT1. Interestingly, MnSOD, a typical NF-κB-
regulated mitochondrial antioxidant enzyme, was suppressed in PC3 cells but enhanced in 
PZ cells treated with AA (Fig. 6A).
Manipulation of RelB expression in cancer cells altered SIRT3 levels, indicating that SIRT3 
is regulated by RelB (Fig. 6B). Subsequently, RT-PCR showed that RelB transcriptionally 
regulated SIRT3 in the AA-treated cells (Fig. 6C). Furthermore, chromatin was pulled down 
by a RelB antibody, and a promoter region of the human SIRT3 gene containing a NF-κB 
element was quantified by qPCR (Fig. 6D). The amount of the pulled down promoter 
fragment was reduced by AA treatment in PC3 cells but increased in AA-treated PZ cells. 
When combined with IR, AA consistently suppressed the activated RelB-SIRT3 signal in 
cancer cells but further activated the RelB-SIRT3 signal in normal cells.
AA enhances radiosensitivity of prostate cancer in vivo
To further confirm our findings in vitro, a tumor-bearing mouse model was used to verify the 
effect of AA on tumor growth. Mice were subcutaneously injected with PC3 cells followed 
by AA and IR treatments. Mice were humanely killed and tumors as well as prostate and 
bladder tissues were collected when the tumor volume reached 1500 mm3. The tumor 
growth rate of each group shown in Fig. 7A demonstrates the efficacy of AA in sensitizing 
prostate cancer to radiation therapy. There was a trend toward significance in the differences 
between AA-treated and untreated mice. The time needed for the tumors in each group to 
reach 1500 mm3 was independently analyzed (Fig. S3A).
mRNA and protein levels of RelB and its targets, SIRT3 and MnSOD, were quantified in the 
extracted tumor tissues. Consistent with the results obtained in vitro, IR increased the levels 
of RelB, SIRT3, and MnSOD, but AA eliminated the increases (Fig. 7B). In addition, 
prostate and bladder tissues were used to probe whether AA activates a protective response 
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against radiation injury in normal tissues. AA increased levels of RelB and SIRT3 mRNA in 
normal prostate and bladder tissues (Fig. 7C).
Overall, AA enhances the radiosensitivity of prostate cancer cells but protects normal cells 
from radiotoxicity through RelB-dependent transcriptional regulation, with consequences for 
downstream target genes, such as SIRT3 and MnSOD, that lead to distinct responses to 
radiation, as illustrated in a working model based on the results obtained to- date (Fig. 7D).
Discussion
The problems of the radioresistance of cancer tissues and the toxic side effects of IR in 
normal tissues have been extensively investigated in both scientific and clinical settings. 
However, traditional approaches have focused on ensuring that protecting normal tissues 
from injury does not also reduce the therapeutic efficacy of radiation. Here, we demonstrate 
that AA, a redox active agent, can enhance the therapeutic efficacy of radiation therapy 
while simultaneously protecting normal tissues against the side effects of radiation therapy.
That AA enhances traditional radiotherapy and chemotherapy of cancer has been reported 
since 1977 (14,15, 32–35). In the intervening decades, AA has been used to alleviate some 
of the side effects of radiation therapy during cancer treatment (34, 36). A recent study by 
Du et al. clearly shows the radiosensitization induced by pharmacological AA in pancreatic 
cancer cells (15). These authors also observed that AA also potentially protects the 
gastrointestinal tract from IR in vivo. Although it was not a major focus of the study, the Du 
et al. observation is consistent with our finding that AA indeed protects normal prostate and 
bladder tissues from IR.
Elevated ROS levels, which are essential for tumorigenesis and metastasis, have been 
observed in many types of cancer. High levels of ROS may reveal a specific vulnerability of 
malignancy that can be used to selectively enhance cell death by further increasing the level 
of cellular ROS. Here, we show that AA acts as a prooxidant at pharmacological doses and 
differentially modulates cellular responses to ROS in normal and cancer cells. Our results 
are consistent with previous studies demonstrating that the cytotoxicity induced by AA is 
primarily mediated by H2O2 (14, 15, 19 and 22). However, the previous studies did not take 
into consideration the respective distinct basal redox state of normal and cancer cells. Our 
data suggest that AA causes an increase in ROS in prostate cancer cells that reaches a 
threshold level of cell death but only slightly increases ROS in normal cells, resulting in an 
induction of antioxidant and metabolic responses. These opposing effects of AA in normal 
and cancer cells are mediated in part by the expression of RelB, a member of the alternative 
pathway of the NF-κB family.
NF-κB is known to be an important ROS-responsive transcriptional factor involved in both 
tumor progression and tumor resistance to treatment (16). Previous studies have indicated 
that AA can inhibit NF-κB activation by preventing the degradation of IκB-α and nuclear 
translocation of RelA (37, 38). Recent studies by our laboratory and others have 
demonstrated that RelB contributes to radioresistance of prostate cancer cells by sustaining 
NF-κB activation (17, 18). The present study further establishes the role of RelB as a critical 
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redox signaling sensor that regulates its downstream target genes in response to AA, leading 
to the observed opposing radiation responses in prostate cancer and normal cells. Repression 
of IR-induced RelB activation in cancer cells results in diminished oxidative defense 
capacity and subsequently enhances radiosensitivity through mitochondrial dysfunction. On 
the contrary, up-regulation of RelB serves as a major mechanism by which AA protects 
normal tissues against radiotoxicity, through up-regulation of antioxidant enzymes and the 
mitochondrial function of scavenging ROS. RelA has been reported to be involved in RelB 
transcriptional activation (39); further studies will be needed to determine whether and how 
RelA participates in a meaningful change of RelB as it relates to AA.
Recently, metabolic alterations in cancer cells due to AA-induced oxidative stress have been 
the subject of intense investigation (15, 40). Although a high rate of aerobic glycolysis in 
tumors, known as the Warburg effect, has been observed in various types of cancer, cancers 
have functional mitochondria, and mitochondrial respiration is necessary for cancer cell 
proliferation and resistance to therapy (41, 42). The present study shows that the 
mitochondria in prostate cancer cells become dysfunctional, with down-regulated MnSOD, 
after AA treatment. As a MnSOD transcriptional regulator, RelB modulation by AA leads to 
the suppression and induction of MnSOD in cancer and normal cells, respectively.
Sirtuins are NAD+-dependent histone deacetylases in mammalian cells and are involved in 
an array of critical cellular functions (43–46). Of the seven human sirtuins, SIRT3 is the best 
characterized in its regulation of many aspects of mitochondrial function. Physiologically, 
SIRT3 interacts with subunits of complexes I and II of the ETC to improve mitochondrial 
respiration (47). SIRT3 also deacetylates and activates MnSOD to maintain the antioxidant 
defense system in cells (48). A recent study described the expression of SIRT3 as a 
sequential action of the SIRT1-RelB axis in a sepsis model (31). The present study suggests 
that the RelB-SIRT3 signaling axis may play a critical role in AA treatment independent of 
SIRT1 levels. Our results demonstrate that RelB regulates SIRT3 expression through binding 
to its promoter region. Repression of RelB-activated SIRT3 transcription by AA aggravates 
metabolic stress in cancer cells. In contrast, up-regulation of SIRT3 improves the ability of 
mitochondria to defend against metabolic stresses in normal cells. These results suggest that 
RelB may be a unique target for treatment of radiation-resistant prostate cancer.
Considering the unsatisfactory results of clinical trials of high doses of oral AA, and the 
reported successes of high doses of intravenous ascorbate (49, 50), the complexity of the 
mechanisms involved in AA treatment deserves further investigation. The present study 
indicates a promising anticancer effect of AA that is dependent on cell properties such as the 
basal redox state of the cancer and normal cells. The present study also reveals cell-
dependent ROS generation in AA treatment and identifies the RelB-SIRT3-MnSOD axis as 
a critical contributor to AA-induced radiosensitization of cancer cells and radioprotection of 
normal cells (Fig. 7D). Thus, while additional mechanistic studies are needed to fully 
understand the biological function of AA, we anticipate that other redox-based anticancer 
therapeutics with protective properties against cytotoxic therapy will be discovered and that 
they will have a significant impact on the care of cancer patients.
Wei et al. Page 11
Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding source: This work was supported mainly by NIH grants CA 049797 and CA 143428 to DK St Clair and 
WH St Clair. Additional support was provided by grants from the National Natural Science Foundation of China 
(Grant No. 81272469) and the Natural Science Foundation of Jiangsu Province (Grant No. BL2012016) to J Chen. 
The research used service facilities funded by a Cancer Center support grant (P30 CA177558).
The authors thank Dr. Mike Mitov and Mr. Michael Alstott of the Redox Metabolism Service Facility at the 
University of Kentucky, who provided technical support for the Seahorse experiments.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29. 
[PubMed: 25559415] 
2. Al-Mamgani A, Lebesque JV, Heemsbergen WD, Tans L, Kirkels WJ, Levendag PC, et al. 
Controversies in the treatment of high-risk prostate cancer: what is the optimal combination of 
hormonal therapy and radiotherapy: a review of literature. Prostate. 2010; 70:701–9. [PubMed: 
20017166] 
3. Nichol A, Chung P, Lockwood G, Rosewall T, Divanbiegi L, Sweet J, et al. A phase II study of 
localized prostate cancer treated to 75. 6 Gy with 3D conformal radiotherapy. Radiother Oncol. 
2005; 76:11–17. [PubMed: 15990187] 
4. Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy 
in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol 
Phys. 2011; 80:1056–63. [PubMed: 21147514] 
5. Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and 
prolonged cell injury. Cancer Lett. 2012; 327:48–60. [PubMed: 22182453] 
6. Skvortsova I, Debbage P, Kumar V, Skvortsov S. Radiation resistance: Cancer stem cells (CSCs) and 
their enigmatic pro-survival signaling. Semin Cancer Biol. 2015; 35:39–44. [PubMed: 26392376] 
7. Droge W. Free radicals in the physiological control of cell function, Physiol. Rev. 2002; 82:47–95.
8. Tang FR, Loke WK. Molecular mechanisms of low dose ionizing radiation-induced hormesis, 
adaptive responses, radioresistance, bystander effects, and genomic instability. Int J Radiat Biol. 
2015; 91:13–27. [PubMed: 24975555] 
9. Creagan ET, Moertel CG, O’Fallon JR, Schutt AJ, O’Connell MJ, Rubin J, et al. Failure of high-
dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. 
N Engl J Med. 1979; 301:687–90. [PubMed: 384241] 
10. Chen Q, Polireddy K, Chen P, Dong R. The unpaved journey of vitamin C in cancer treatment. Can 
J Physiol Pharmacol. 2015; 93:1055–63. [PubMed: 26469874] 
11. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, et al. Vitamin C 
pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med. 2004; 140:533–37. 
[PubMed: 15068981] 
12. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, et al. Phase I evaluation of 
intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic 
pancreatic cancer. PLoS One. 2012; 7:e29794. [PubMed: 22272248] 
13. Welsh JL, Wagner BA, Van’t Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, et al. Pharmacological 
ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer 
(PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar.71:765–
75. [PubMed: 23381814] 
14. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, et al. Ascorbate in pharmacologic 
concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid 
in vivo. Proc Natl Acad Sci USA. 2007; 104:8749–54. [PubMed: 17502596] 
Wei et al. Page 12
Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
15. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, et al. Mechanisms of ascorbate-
induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010; 16:509–20. [PubMed: 
20068072] 
16. Ahmed KM, Zhang H, Park CC. NF-κB regulates radioresistance mediated by β1-integrin in three-
dimensional culture of breast cancer cells. Cancer Res. 2013; 73:3737–48. [PubMed: 23576567] 
17. Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-
kB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005; 
93:1019–23. [PubMed: 16205698] 
18. Xu Y, Fang F, Sun Y, St Clair DK, St Clair WH. RelB-dependent differential radiosensitization 
effect of STI571 on prostate cancer cells. Mol Cancer Ther. 2010; 9:803–12. [PubMed: 20371728] 
19. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, 
tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced 
cancer. Cancer Chemother Pharmacol. 2013; 72:139–46. [PubMed: 23670640] 
20. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay 
method. Cancer Res. 2010; 70:440–46. [PubMed: 20068163] 
21. Xu Y, Josson S, Fang F, St Clair DK, Wan XS, Sun Y, et al. RelB enhances prostate cancer growth: 
implications for the role of the NF-kB alternative pathway in tumorigenicity. Cancer Res. 2009; 
69:3267–71. [PubMed: 19351823] 
22. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. Phase I clinical 
trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008; 19:1969–74. [PubMed: 
18544557] 
23. Weydert CJ, Waugh TA, Ritchie JM, Iyer KS, Smith JL, Li L, Spitz DR, Oberley LW. 
Overexpression of manganese or copper zinc superoxide dismutase inhibits breast cancer growth. 
Free Radic Biol Med. 2006; 41:226–237. [PubMed: 16814103] 
24. Weydert C, Roling B, Liu J, Hinkhouse MM, Ritchie JM, Oberley LW, Cullen JJ. Suppression of 
the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese 
superoxide dismutase. Mol Cancer Ther. 2003; 2:361–369. [PubMed: 12700280] 
25. Liu R, Fan M, Candas D, Qin L, Zhang X, Eldridge A, et al. CDK1-Mediated SIRT3 Activation 
Enhances Mitochondrial Function and Tumor Radioresistance. Mol Cancer Ther. 2015; 14:2090–
102. [PubMed: 26141949] 
26. Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, et al. KEAP1 is a redox sensitive 
target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. 
Cancer Res. 2013; 73(14):4406–17. [PubMed: 23674500] 
27. Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, et al. The radiosensitization 
effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and 
enhanced by the presence of PTEN. Mol Cancer Ther. 2007; 6:2477–86. [PubMed: 17876045] 
28. Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. Vitamin C selectively kills KRAS 
and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015; 350:1391–96. 
[PubMed: 26541605] 
29. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011; 
21:103–15. [PubMed: 21187859] 
30. Holley AK, Xu Y, St Clair DK, St Clair WH. RelB regulates manganese superoxide dismutase 
gene and resistance to ionizing radiation of prostate cancer cells. Ann N Y Acad Sci. 2010; 
1201:129–36. [PubMed: 20649549] 
31. Liu TF, Vachharajani V, Millet P, Bharadwaj MS, Molina AJ, McCall CE. Sequential actions of 
SIRT1-RELB-SIRT3 coordinate nuclear-mitochondrial communication during immunometabolic 
adaptation to acute inflammation and sepsis. J Biol Chem. 2015; 290:396–408. [PubMed: 
25404738] 
32. Davis-Yadley AH, Malafa MP. Vitamins in Pancreatic Cancer: A Review of Underlying 
Mechanisms and Future Applications. Adv Nutr. 2015; 6:774–802. [PubMed: 26567201] 
33. Du J, Cieslak JA 3rd, Welsh JL, Sibenaller ZA, Allen BG, Wagner BA, Kalen AL, Doskey CM, 
Strother RK, Button AM, Mott SL, Smith B, Tsai S, Mezhir J, Goswami PC, Spitz DR, Buettner 
GR, Cullen JJ. Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Cancer Res. 2015 
Aug 15; 75(16):3314–26. [PubMed: 26081808] 
Wei et al. Page 13
Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
34. O’Connor MK, Malone JF, Moriarty M, Mulgrew S. A radioprotective effect of vitamin C 
observed in Chinese hamster ovary cells. Br J Radiol. 1977; 50:587–91. [PubMed: 890235] 
35. Hosokawa Y, Monzen S, Yoshino H, Terashima S, Nakano M, Toshima K, et al. Effects of X-ray 
irradiation in combination with ascorbic acid on tumor control. Mol Med Rep. 2015; 12:5449–54. 
[PubMed: 26238154] 
36. Halperin EC, Gaspar L, George S, Darr D, Pinnell S. A double-blind, randomized, prospective trial 
to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer 
Consortium. Int J Radiat Oncol Biol Phys. 26:413–16. 199. 
37. Han SS, Kim K, Hahm ER, Lee SJ, Surh YJ, Park HK, et al. L-ascorbic acid represses constitutive 
activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell 
Biochem. 2004; 93:257–70. [PubMed: 15368354] 
38. Cárcamo JM1, Pedraza A, Bórquez-Ojeda O, Zhang B, Sanchez R, Golde DW. Vitamin C is a 
kinase inhibitor: dehydroascorbic acid inhibits IkappaBalpha kinase beta. Mol Cell Biol. 2004; 
24:6645–52. [PubMed: 15254232] 
39. Bren GD, Solan NJ, Miyoshi H, Pennington KN, Pobst LJ, Paya CV. Transcription of the RelB 
gene is regulated by NF-kappaB. Oncogene. 2001; 20:7722–33. [PubMed: 11753650] 
40. Uetaki M, Tabata S, Nakasuka F, Soga T, Tomita M. Metabolomic alterations in human cancer 
cells by vitamin C-induced oxidative stress. Sci Rep. 2015; 5:13896. [PubMed: 26350063] 
41. Weinberg F, Chandel NS. Mitochondrial metabolism and cancer. Ann NY Acad Sci. 2009; 
1177:66–73. [PubMed: 19845608] 
42. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth 
S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao 
W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, 
Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer 
cells depend on mitochondrial function. Nature. 2014 Oct 30; 514(7524):628–32. [PubMed: 
25119024] 
43. Schumacker PT. A tumor suppressor SIRTainty. Cancer Cell. 2010; 17:5–6. [PubMed: 20129243] 
44. Wu YT, Wu SB, Wei YH. Roles of sirtuins in the regulation of antioxidant defense and 
bioenergetic function of mitochondria under oxidative stress. Free Radic Res. 2014; 48(9):1070–
84. [PubMed: 24797412] 
45. Parihar P, Solanki I, Mansuri ML, Parihar MS. Mitochondrial sirtuins: emerging roles in metabolic 
regulations, energy homeostasis and diseases. Exp Gerontol. 2015 Jan.61:130–41. [PubMed: 
25482473] 
46. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, et al. Sirt3 mediates reduction of 
oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010; 
143:802–12. [PubMed: 21094524] 
47. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D’Silva NJ, et al. Sirtuin-3 (SIRT3), a 
novel potential therapeutic target for oral cancer. Cancer. 2011; 117:1670–78. [PubMed: 
21472714] 
48. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, 
Hayes McDonald W, Olivier AK, Spitz DR, Gius D. Sirt3-mediated deacetylation of evolutionarily 
conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010 Dec 22; 
40(6):893–904. [PubMed: 21172655] 
49. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, et al. Pharmacologic 
ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen 
peroxide to tissues. Proc Natl Acad Sci USA. 2005; 102:13604–609. [PubMed: 16157892] 
50. Welsh JL, Wagner BA, van’t Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, 
Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate 
with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): 
results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar; 71(3):765–75. 
[PubMed: 23381814] 
Wei et al. Page 14
Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 1. 
The effect of AA on proliferation and radiosensitivity of prostate cancer and normal cells. A, 
Two prostate cancer cell lines (PC3 and LNCaP) and one prostate epithelial cell line (PZ) 
were treated with different concentrations of AA. Cell survival fraction was determined by 
colony survival analysis. *, # P<0.001 comparing PZ cells to PC3 (*) and LNCaP (#) cells, 
respectively. @ P<0.001 comparing LNCaP and PC3 cells. B, Two prostate cancer cell lines 
(PC3 and LNCaP) and two prostate epithelial cell lines (PZ and PrEC) were treated with 
different concentrations of AA. Cell survival fraction was determined by MTT assay. IC50 
for each cell line was calculated based on the dose-response curve. *, #, & P<0.001 
comparing PC3 cells to PZ (*), LNCaP (#) and PrEC (&) cells, respectively. @, $ P<0.001 
comparing LNCaP cells to PZ (@) and PrEC ($) cells, respectively. C, Prostate cancer PC3 
cells and prostate epithelial PZ cells were treated with IR and AA at indicated doses. Cell 
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survival fraction was determined by MTT assay. *, # P<0.001 comparing IR group to IR
+2mM (#) and IR+4mM (*) groups, respectively. @ P<0.001 comparing IR+2mM and IR
+4mM groups. All the analyses were performed using linear regression models and 
Likelihood ratio tests with Bonferroni correction.
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Figure 2. 
The effect of AA on redox homeostasis in prostate cancer and normal cells. A, Prostate 
cancer and normal epithelial cells were treated with AA and then incubated with Amplex 
Red. The extracellular H2O2 concentration was calculated by a standard curve and 
normalized to the cell number. B, Concentrations of mitochondrial superoxide in PC3 and 
PZ cells were measured by MitoSox Red after treatment with AA and IR as indicated. 
Cellular fluorescence intensity was detected by fluorescence microscopy and a fluorescence 
microplate reader. Mitochondria were visualized by staining with Mitotracker Green. 
Microplate readings were normalized by protein levels. n.s, no significance detected. All the 
analyses were performed using one-way ANOVA with post-hoc Tukey HSD test.
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Figure 3. 
The effect of AA on metabolic homeostasis in prostate cancer and normal cells. A, After AA 
treatment, OCR in PC3 and PZ cells was measured by a Seahorse Bioscience XF96 
OxygenFlux Analyzer. B, Intracellular ATP levels were measured after treatment with AA 
and IR at the indicated doses. C and D, Extracellular and intracellular lactate levels. Two-
tailed Student’s t test was performed for comparisons of treated groups to control groups in 
OCR test. One-way ANOVA with post-hoc Tukey HSD test was performed for comparisons 
of multiple groups in cells. n.s. represents non-statistical significance.
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Figure 4. 
Differential regulation of RelB by AA in prostate cancer and normal cells. A, After AA 
treatment, the expression levels of RelA and RelB were quantified by western blots and RT-
PCR. B, Nuclear extracts from the treated and untreated cells were subjected to the NF-κB 
binding assay kit. Binding activities of RelA and RelB were determined by ELISA analysis. 
C, RelB was overexpressed in LNCaP cells and silenced in PC3 cells by cell transfection, 
and the cells were treated with different concentrations of AA. Cell survival fraction was 
determined by MTT assay. * P<0.001 comparing LNCaP-RelB and LNCaP-Vector cells; # 
P<0.001 comparing PC3-siRelB and PC3-Vector cells based on Linear regression models 
and Likelihood ratio tests with Bonferroni correction. Other data were analyzed using one-
way ANOVA with post-hoc Tukey HSD test.
Wei et al. Page 19
Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 5. 
The regulation of RelB on redox and metabolic homeostasis. A, Intracellular ATP levels, 
extracellular and intracellular lactate levels were measured after treatment with AA and IR at 
the indicated doses in PC3 and in RelB-silenced PC3 cells. B, After AA and IR treatment, 
OCR in PC3 and in RelB-silenced PC3 cells was measured by a Seahorse Bioscience XF96 
OxygenFlux Analyzer. C, The level of cellular ROS was estimated by the ratio of 
H2DCFDA to Carboxy-DCFDA. PEG-Catalase was used as a control to remove ROS 
generated by AA. D, Catalase activity, Gpx activity and MnSOD activity were measured 
after treatment with AA and IR in PC3 and in RelB-silenced PC3 cells. Two-tailed Student’s 
t test was performed for comparisons of RelB- silenced group to control group.
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Figure 6. 
Modulation of SIRT3 due to AA-mediated RelB regulation. A, After AA treatment, the 
expression of SIRT1, SIRT3, RelB, and MnSOD in PC3 and PZ cells was measured by 
western blots. B, Protein levels of SIRT1 and SIRT3 after manipulation of RelB expression 
in LNCaP and PC3 cells were determined by western blots. C, After AA treatment, mRNA 
levels of SIRT3 in PC3 cells and PZ cells were determined by RT-PCR. D, Protein–DNA 
complexes were extracted from the AA-treated or untreated PC3 and PZ cells and then 
immunoprecipitated using a RelB antibody. The SIRT3 promoter fragment containing a NF-
κB element was amplified by q-PCR with specific primers, which were normalized by their 
input controls containing relevant unprecipitated chromatin. E, After AA and radiation 
treatment, the expression of RelB-SIRT3 in PC3 and PZ cells was measured by western 
blots. One-way ANOVA with post-hoc Tukey HSD test was performed for comparison of 
multiple groups in cells.
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Figure 7. 
AA-mediated radiosensitization of prostate cancer cells in vivo. A, Prostate cancer PC3 cells 
were injected into the flanks of nude male mice and the formed tumors were treated with 
AA and IR as indicated. Tumor volume was measured and tumor growth rate was calculated. 
Kaplan-Meier survival curves and the log-rank test were performed for comparison of the 
survival curves. B, The levels of RelB, SIRT3, and MnSOD in tumor tissue were measured 
by western blots and RT-PCR. C, mRNA levels of RelB and SIRT3 in prostate and bladder 
tissues were quantified by RT-PCR. D, A proposed mechanistic model for the AA-mediated 
differential response to radiation in prostate cancer and normal cells. AA sensitizes cancer 
cells to radiation by down-regulating RelB-SIRT3 signal, which in turn aggravates oxidative 
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and metabolic stresses. In contrast, in normal prostate epithelial cells, H2O2 generated from 
the redox reaction of AA up-regulates RelB, leading to increased SIRT3 levels, which 
enhances cellular stress defense systems. Kaplan-Meier survival curves and the log-rank test 
were performed for comparison of the survival curves in animal experiments. Other data 
were analyzed using one-way ANOVA with post-hoc Tukey HSD test.
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